LILLE, France (TheStreet) -- Torture a prisoner long enough and he'll tell you what you want to hear. Clinical trials are similarly vulnerable. Just ask Genfit , which put its fatty liver drug candidate GFT505 through the statistical equivalent of waterboarding and sleep deprivation to extract the desired result from a mid-stage study: The drug works! But GFT505 achieved the primary endpoint of the study -- clearance of nonalcoholic steatohepatitis (NASH) -- only after excluding placebo patients who responded really well.